First Wave BioPharma to Receive Global License for Capeserod from Sanofi in Gastrointestinal Disorders
- Sanofi will receive $500,000 up front within 30 business days, ~$46M in development & regulatory milestones, and ~$235M in commercial milestones along with royalties. The agreement focuses on expanding First Wave’s GI-focused pipeline
- First Wave to get an exclusive license globally for Capeserod (a selective 5-HT4 receptor partial agonist) & will be responsible for all future clinical development. Sanofi gets the right of first refusal to reacquire Capeserod following certain stages of clinical development and to commercialize the product
- First Wave will repurpose & develop for GI indications, discuss with the US FDA for development & regulatory plan for Capeserod in GI disease with planning to initiate the P-II trials of Capeserod in 2024
Ref: Globenewswire | Image: Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.